VAXART
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a conven... ient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.
VAXART
Industry:
Biotechnology Health Care Medical Device
Founded:
2004-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.vaxart.com
Total Employee:
101+
Status:
Active
Contact:
8667032712
Email Addresses:
[email protected]
Total Funding:
138.67 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress LetsEncrypt HSTS IPv6
Similar Organizations
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Attest Laboratories
Attest Laboratories is a biotechnology company that develops the next generation of biomarker test technology for healthcare providers.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
CVRx
CVRx is a medical device company developing implantable technology for the treatment of high blood pressure.
Hilab
Hilab is a technology company that develops biomedical equipment and telemedicine technology for the humanization of health care.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
ViewRay
ViewRay is a medical company that develops radiation therapy technology for the treatment of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-10-30 | Aviragen Therapeutics | Aviragen Therapeutics acquired by Vaxart | N/A |
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Venture Round - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series D - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series C - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series B - Vaxart
Care Capital
Care Capital investment in Series B - Vaxart
Quantum Technology Partners
Quantum Technology Partners investment in Series B - Vaxart
Life Science Angels
Life Science Angels investment in Series B - Vaxart
Mason Ng
Mason Ng investment in Series B - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series B - Vaxart
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-06 | Vaxart appoints Steven Lo as president, CEO, and director |
| 2022-12-19 | Vaxart Names Phillip Lee as Chief Financial Officer |
| 2022-02-14 | Vaxart Appoints Edward Berg as Senior Vice President and General Counsel |
| 2021-09-27 | Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer |
Official Site Inspections
http://www.vaxart.com Semrush global rank: 2.59 M Semrush visits lastest month: 6.97 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vaxart"
About - Vaxart Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable pills that can be …See details»
Vaxart - Wikipedia
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Te…See details»
Vaxart, Inc. - LinkedIn
Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including...See details»
Vaxart Company Profile 2024: Stock Performance
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.See details»
Vaxart, Inc. Company Profile | South San Francisco, CA
Find company research, competitor information, contact details & financial data for Vaxart, Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
Corporate Insiders Pocket $1 Billion in Rush for …
Jul 25, 2020 · On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of...See details»
Vaxart Announces Creation of New Scientific and …
Aug 19, 2021 · SOUTH SAN FRANCISCO, Calif., Aug. 19, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.See details»
Vaxart Announces Creation of Manufacturing and Quality Advisory …
Sep 21, 2021 · SOUTH SAN FRANCISCO, Calif., Sept. 21, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory …See details»
VXRT Stock Quote Price and Forecast | CNN
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized …See details»
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule …
Nov 19, 2024 · Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed …See details»
Vaxart Provides Business Update and Reports Second Quarter …
Aug 5, 2021 · Vaxart, a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced its business …See details»
U.S. Investigates Vaxart’s Claims Related to Covid-19 Vaccine
Oct 15, 2020 · Vaxart, a California biotech firm that is attempting to develop a Covid-19 vaccine, has come under scrutiny from federal prosecutors and the Securities and Exchange Commission.See details»
Vaxart Announces FDA Clearance of IND Application for Oral
Sep 14, 2020 · --Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the U.S. Food …See details»
Vaxart, Inc. (VXRT) Stock Price, News, Quote & History - Yahoo …
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.See details»
Vaxart Provides Business Update and Reports Third Quarter 2024 ...
Nov 13, 2024 · Vaxart continues to anticipate cash runway into 2026. Vaxart reported a net loss of $14.1 million for the third quarter of 2024, compared to $17.4 million for the third quarter of 2023.See details»
Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet ...
Oct 6, 2021 · Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month. The company's Phase II …See details»
VXRT Stock Price Quote - Morningstar
Nov 21, 2024 · Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.See details»
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID …
Aug 2, 2021 · Vaxart (www.vaxart.com) is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines …See details»
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet …
Oct 26, 2021 · SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in its Phase II COVID-19 …See details»